Free Trial

Humana (HUM) Stock Price, News & Analysis

Humana logo
$298.11 +2.40 (+0.81%)
(As of 11/22/2024 ET)

About Humana Stock (NYSE:HUM)

Key Stats

Today's Range
$295.41
$303.03
50-Day Range
$236.27
$319.52
52-Week Range
$213.31
$527.18
Volume
1.45 million shs
Average Volume
2.08 million shs
Market Capitalization
$35.90 billion
P/E Ratio
26.40
Dividend Yield
1.19%
Price Target
$315.86
Consensus Rating
Hold

Company Overview

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Humana Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
89th Percentile Overall Score

HUM MarketRank™: 

Humana scored higher than 89% of companies evaluated by MarketBeat, and ranked 132nd out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Humana has received a consensus rating of Hold. The company's average rating score is 2.24, and is based on 6 buy ratings, 19 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Humana has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Humana's stock forecast and price target.
  • Earnings Growth

    Earnings for Humana are expected to grow by 5.04% in the coming year, from $15.86 to $16.66 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Humana is 26.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.99.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Humana is 26.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.36.

  • Price to Earnings Growth Ratio

    Humana has a PEG Ratio of 2.33. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Humana has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Humana's valuation and earnings.
  • Percentage of Shares Shorted

    3.65% of the float of Humana has been sold short.
  • Short Interest Ratio / Days to Cover

    Humana has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Humana has recently increased by 15.87%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Humana pays a meaningful dividend of 1.20%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Humana does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Humana is 31.36%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Humana will have a dividend payout ratio of 21.25% next year. This indicates that Humana will be able to sustain or increase its dividend.

  • Read more about Humana's dividend.
  • Percentage of Shares Shorted

    3.65% of the float of Humana has been sold short.
  • Short Interest Ratio / Days to Cover

    Humana has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Humana has recently increased by 15.87%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Humana has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 31 news articles for Humana this week, compared to 22 articles on an average week.
  • Search Interest

    Only 22 people have searched for HUM on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.
  • MarketBeat Follows

    23 people have added Humana to their MarketBeat watchlist in the last 30 days. This is an increase of 64% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Humana insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.32% of the stock of Humana is held by insiders.

  • Percentage Held by Institutions

    92.38% of the stock of Humana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Humana's insider trading history.
Receive HUM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humana and its competitors with MarketBeat's FREE daily newsletter.

HUM Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 10/28 - 11/1 (HUM)
Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment
Health care and medical services concept with flat line AR interface.medical techonlogy concept,smart doctor hand working with modern laptop computer in modern office with virtual icon diagram - stock image
Cigna Considers Humana Acquisition – What It Means for the Stocks
Rumors swirl around a potential Cigna (CI) and Humana (HUM) merger, but Medicare Advantage costs pose a significant challenge, making the merger risky.
Let’s be blunt
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
Humana Stock: Analyst Estimates & Ratings
Big Changes Are Coming to Medicare in 2025
Humana (HUM) Receives a Buy from Wells Fargo
Humana price target raised to $315 from $290 at Wells Fargo
See More Headlines

HUM Stock Analysis - Frequently Asked Questions

Humana's stock was trading at $457.81 at the beginning of 2024. Since then, HUM shares have decreased by 34.9% and is now trading at $298.11.
View the best growth stocks for 2024 here
.

Humana Inc. (NYSE:HUM) announced its earnings results on Wednesday, October, 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts' consensus estimates of $3.48 by $0.68. The insurance provider had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a trailing twelve-month return on equity of 13.20% and a net margin of 1.18%.
Read the conference call transcript
.

The following companies are subsidiaries of Humana: Enclara Healthcare, Kindred Healthcare, American Eldercare, FPG, Metropolitan Health Networks, Certify Data Systems, Harris Rothenberg International, and others.

Humana's top institutional investors include State Street Corp (4.45%), Wellington Management Group LLP (3.81%), FMR LLC (2.81%) and Geode Capital Management LLC (2.34%). Insiders that own company stock include Bruce D Broussard, David A Jr/Ky Jones, Samir Deshpande, Timothy S Huval, Joseph C Ventura, Susan M Diamond, Jorge S Mesquita and William Kevin Fleming.
View institutional ownership trends
.

Shares of HUM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Humana investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Ex-Dividend for 10/25 Dividend
9/30/2024
Dividend Payable
10/25/2024
Last Earnings
10/30/2024
Today
11/23/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
1/23/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Hospital & medical service plans
Sub-Industry
Managed Health Care
CUSIP
44485910
Employees
67,600
Year Founded
1961

Price Target and Rating

Average Stock Price Target
$315.86
High Stock Price Target
$550.00
Low Stock Price Target
$250.00
Potential Upside/Downside
+6.0%
Consensus Rating
Hold
Rating Score (0-4)
2.24
Research Coverage
25 Analysts

Profitability

Net Income
$2.49 billion
Pretax Margin
1.73%

Debt

Sales & Book Value

Annual Sales
$106.37 billion
Cash Flow
$34.54 per share
Book Value
$146.37 per share

Miscellaneous

Free Float
120,026,000
Market Cap
$35.90 billion
Optionable
Optionable
Beta
0.52

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NYSE:HUM) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners